The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Autologous heat shock protein vaccine (HSPPC-96) for patients with recurrent glioblastoma (GBM): Results of a phase II multicenter clinical trial with immunological assessments.
A. Parsa
No relevant relationships to disclose
C. Crane
No relevant relationships to disclose
S. Han
No relevant relationships to disclose
V. Kivett
No relevant relationships to disclose
A. Fedoroff
No relevant relationships to disclose
N. A. Butowski
No relevant relationships to disclose
S. M. Chang
No relevant relationships to disclose
J. L. Clarke
No relevant relationships to disclose
M. S. Berger
No relevant relationships to disclose
M. McDermott
No relevant relationships to disclose
M. Aghi
No relevant relationships to disclose
C. Yanes
No relevant relationships to disclose
M. Prados
No relevant relationships to disclose
A. E. Sloan
No relevant relationships to disclose
J. N. Bruce
No relevant relationships to disclose